Tyra Biosciences, Experiences Significant Stock Sale from Daniel Bensen
April 8, 2023
Trending News ☀️
Daniel Bensen, a major shareholder of Tyra Biosciences ($NASDAQ:TYRA), Inc. (NASDAQ:TYRA), has disposed of 8048 shares of the company’s stock. Tyra Biosciences, Inc. is a biotechnology company focusing on the development of therapeutics for cancer patients. The company is dedicated to developing precision therapies, such as small molecule drugs and immunotherapies, that specifically target cancer cells and tumors, while minimizing damage to healthy cells and tissues.
Tyra Biosciences has an experienced team of scientists and backing from major venture capital firms. Tyra Bioscience’s aim is to provide treatments that improve patient outcomes, reduce treatment costs, and increase the success rate of drug development.
Price History
On Monday, TYRA BIOSCIENCES, Inc. experienced a significant stock sale from Daniel Bensen. The sale saw the company’s stock open at $16.0 and close at the same rate, representing a 0.4% decrease from its prior closing price of $16.1. This sale could be indicative of a larger trend in the company’s stock and is worth monitoring in the coming weeks to see if the value continues to fall. As such, investors and interested parties alike should keep an eye on the market to stay informed of TYRA BIOSCIENCES’ performance. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Tyra Biosciences. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -55.33 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tyra Biosciences. More…
| Operations | Investing | Financing |
| -50.28 | -0.56 | 0.63 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tyra Biosciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 266.18 | 8.35 | 6.35 |
Key Ratios Snapshot
Some of the financial key ratios for Tyra Biosciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | – |
| FCF Margin | ROE | ROA |
| – | -14.0% | -13.8% |
Analysis
At GoodWhale, we just completed an analysis of TYRA BIOSCIENCES‘ wellbeing and the results were mixed. According to our Risk Rating, TYRA BIOSCIENCES is a medium risk investment in terms of financial and business aspects. This means that investors should be aware of potential risks and take steps to protect their investments. While the overall Risk Rating is medium, we did detect one risk warning in the cashflow statement. To get the full picture and determine if TYRA BIOSCIENCES is suitable for you, we suggest registering on GoodWhale.com to check out our detailed analysis of TYRA BIOSCIENCES. More…
Peers
The competition in the biosciences industry is fierce, with Tyra Biosciences Inc competing against Tenaya Therapeutics Inc, Cogent Biosciences Inc, and Kronos Bio Inc. All four companies are striving to develop new and innovative treatments for various diseases and conditions. While each company has its own strengths and weaknesses, Tyra Biosciences Inc is confident that it has what it takes to emerge victorious in the competition.
– Tenaya Therapeutics Inc ($NASDAQ:TNYA)
Tenaya Therapeutics Inc is a clinical stage biopharmaceutical company. The company’s focus is on developing treatments for patients with muscular dystrophies. The company’s lead product candidate is a microdystrophin gene therapy for the treatment of Duchenne muscular dystrophy.
– Cogent Biosciences Inc ($NASDAQ:COGT)
Cogent Biosciences Inc is a clinical-stage biotechnology company that focuses on developing precision medicines for patients with genetically defined diseases. The company’s market cap is $786.3M as of 2022 and its ROE is -26.61%. The company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in clinical development for the treatment of advanced solid tumors and hematologic malignancies.
– Kronos Bio Inc ($NASDAQ:KRON)
Kronos Bio Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of next-generation therapeutics for the treatment of cancer. The Company’s product candidates are designed to target cancer cells and deliver payloads to kill cancer cells. The Company’s lead product candidates include KRONOS-002, which is in Phase I/II clinical trials for the treatment of solid tumors, and KRONOS-004, which is in Phase I clinical trials for the treatment of hematologic malignancies.
Summary
Daniel Bensen has recently sold 8048 shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) stock, which has been volatile lately. Investors should keep an eye on the stock price and volume of Tyra Biosciences to get an idea of its direction in the near future. It is important to analyze any news and research reports related to the company in order to gain insight into its potential performance.
Additionally, keeping track of key indicators such as sales, earnings, and cash flow can help investors determine the company’s financial health. Technical analysis can also be used to identify entry and exit points in the stock. Overall, investors should be aware of the risks associated with investing in TYRA BIOSCIENCES and should perform their own due diligence before making any investment decisions.
